Last reviewed · How we verify
HyperAcute-Prostate Cancer Vaccine
HyperAcute-Prostate Cancer Vaccine is a Biologic drug developed by NewLink Genetics Corporation. It is currently in Phase 1 development.
At a glance
| Generic name | HyperAcute-Prostate Cancer Vaccine |
|---|---|
| Sponsor | NewLink Genetics Corporation |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Vaccine Treatment for Hormone Refractory Prostate Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HyperAcute-Prostate Cancer Vaccine CI brief — competitive landscape report
- HyperAcute-Prostate Cancer Vaccine updates RSS · CI watch RSS
- NewLink Genetics Corporation portfolio CI
Frequently asked questions about HyperAcute-Prostate Cancer Vaccine
What is HyperAcute-Prostate Cancer Vaccine?
HyperAcute-Prostate Cancer Vaccine is a Biologic drug developed by NewLink Genetics Corporation.
Who makes HyperAcute-Prostate Cancer Vaccine?
HyperAcute-Prostate Cancer Vaccine is developed by NewLink Genetics Corporation (see full NewLink Genetics Corporation pipeline at /company/newlink-genetics-corporation).
What development phase is HyperAcute-Prostate Cancer Vaccine in?
HyperAcute-Prostate Cancer Vaccine is in Phase 1.